Goldman Sachs Upgrades MorphoSys to Neutral, Raises Price Target to $9.25
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Rajan Sharma has upgraded MorphoSys from Sell to Neutral and raised the price target from $3.5 to $9.25.
September 15, 2023 | 8:11 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MorphoSys has been upgraded from Sell to Neutral by Goldman Sachs, with a raised price target of $9.25.
The upgrade from Sell to Neutral indicates a more positive outlook for MorphoSys by Goldman Sachs. The significant increase in the price target from $3.5 to $9.25 suggests that the analyst sees potential for the stock's price to rise in the short term. This could lead to increased investor interest and potentially a rise in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100